Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

TL;DR: A review of the development and physiological functions of B cells and the main mechanisms through which B cells are thought to contribute to CNS auto-immunity is provided in this article, with a focus on the effects on B cell subsets.

TL;DR: Overall, in clinical trials, VZV rates of infection were low but higher with fingolimod compared with placebo, and a similar rate was confirmed in the ongoing extension studies.

TL;DR: The alemtuzumab clinical development program used an active comparator, subcutaneous interferon beta-1a, to show that alemTuzumAB is a highly efficacious disease-modifying therapy, with benefits on relapses, disability outcomes, and freedom from clinical disease and magnetic resonance imaging activity.

TL;DR: Combining evidence shows that effective intervention during a limited period early in the course of MS is critical for maintaining neurological function and preventing subsequent disability, and the advent of new MS therapies and evolving management strategies offer exciting new opportunities to optimize treatment outcomes.

TL;DR: New evidence and consensus now strengthen the role of these criteria in the multiple sclerosis diagnostic workup to demonstrate dissemination of lesions in time, to clarify the use of spinal cord lesions, and to simplify diagnosis of primary progressive disease.

TL;DR: In this article, the authors derived the asymptotic distribution of the maximum partial likelihood estimator β for the vector of regression coefficients β under a possibly misspecified Cox proportional hazards model.

TL;DR: This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.

TL;DR: The history of clinical diagnostic criteria demonstrates the evolution from rather tentative classifications of restricted value to the more elaborate 1983 scheme which incorporates some laboratory procedures under the rubric paraclinical tests as well as a new category based on the presence of specific abnormalities of the cerebrospinal fluid (CSF).